Core Viewpoint - AN2 Therapeutics, Inc. (ANTX) has experienced a downtrend with a 5.5% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Stock Performance and Indicators - The stock has been under significant selling pressure, indicated by an RSI reading of 24.66, which suggests it is oversold [4]. - A stock is generally considered oversold when its RSI falls below 30, and ANTX's current RSI indicates a potential reversal in trend [2]. Group 2: Earnings Estimates and Analyst Consensus - Over the last 30 days, the consensus EPS estimate for ANTX has increased by 4.1%, reflecting a strong agreement among analysts regarding improved earnings [4]. - ANTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a favorable outlook for a turnaround [5].

Financial Performance - For the three months ended March 31, 2024, the net loss was $16.6 million, compared to a net loss of $15.3 million for the same period in 2023, representing an 8% increase in losses [116]. - The company has incurred an accumulated deficit of $171.1 million as of March 31, 2024 [116]. - Net losses for Q1 2024 were $16.6 million, compared to $15.3 million in Q1 2023, with an accumulated deficit of $171.1 million as of March 31, 2024 [132]. - Cash used in operating activities was $17.6 million in Q1 2024, compared to $11.6 million in Q1 2023 [144]. - Other income increased to $1.7 million in Q1 2024, compared to $0.7 million in Q1 2023, driven by higher interest rates and cash balances [131]. Expenses - Research and development expenses increased to $14.7 million for the three months ended March 31, 2024, up from $12.0 million in the same period of 2023, marking a 22% increase [125]. - Total operating expenses for the first quarter of 2024 were $18.3 million, a 14% increase from $16.0 million in the first quarter of 2023 [125]. - Clinical trial expenses increased by $3.7 million in 2024 due to higher enrollment and related activities [127]. - Clinical trials expenses increased to $5.8 million in Q1 2024, up 175% from $2.1 million in Q1 2023 [129]. - General and administrative expenses decreased to $3.6 million in Q1 2024 from $4.1 million in Q1 2023, a decrease of 10% [125]. - General and administrative expenses decreased to $3.6 million in Q1 2024, down from $4.1 million in Q1 2023, primarily due to reduced professional services costs [130]. Funding and Cash Position - The company had cash, cash equivalents, and investments totaling $118.1 million as of March 31, 2024, which is expected to fund operations for at least the next twelve months [117]. - The company raised gross proceeds of $70.0 million from an underwritten offering in August 2023, with net proceeds of $65.5 million after expenses [116]. - The company expects to require substantial additional funding to support ongoing operations and product development [134]. - Future funding may be sought through public or private equity offerings or debt financings, which could result in dilution for existing shareholders [135]. - The company had cash, cash equivalents, and investments totaling $118.1 million as of March 31, 2024, primarily in money market funds and investment-grade securities [154]. Regulatory and Operational Plans - The Phase 2 portion of the clinical trial for epetraborole has completed enrollment, with topline data expected in August 2024 [115]. - The company plans to hire a specialty sales force if regulatory approval for epetraborole is obtained, which will increase operating costs [118]. - The company has not generated any revenue from contracts with customers and does not expect to do so until regulatory approval is obtained for its product candidates [134]. Market and Economic Conditions - A hypothetical 10% relative change in interest rates would not have had a material impact on the company's financial statements [155]. - The company was not exposed to material foreign currency risk during the quarter ended March 31, 2024 [156]. - Inflation has not had a material effect on the company's unaudited condensed financial statements [157]. - The company intends to remain an Emerging Growth Company (EGC) until it exceeds $1.235 billion in total annual revenues or meets other specified criteria [153].

Exhibit 99.1 AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determined after review of unblinded Phase 2 data and discussions with the FDA Cash, cash equivalents, and in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41331 AN2 Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-0606654 (State or other jurisdiction ...

Exhibit 99.1 AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents and investments of $134.5 million at December 31, 2023 Menlo Park, CA – March 28, 2024 – AN2 The ...

BOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating AN2 Therapeutics, Inc. (NASDAQ:ANTX) for potential securities law violations. Investors who have lost money in their AN2 Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/antx. What is this all about? Before the market open on February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamles ...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the company’s decision to voluntarily pause Phase 3 enrollment in the seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review. The double-blind, placebo-controlled trial has two arms compa ...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. Details of the event is as follows: Oppenheimer 34th Annual Healthcare Life Sciences Conference (virtual) Eric Easom, Co-Founder, Presiden ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock aliv ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ | --- | --- | |----------------------------------------------------------------------------------------------------------------------|------- ...